Dr. Reddy's Options Hit a 52-Week Extreme Before Thursday Results

Dr. Reddy's Laboratories reports its next quarterly results on October 30, and the options market has moved to its most defensive reading of the past year in the days since the October 23 print landed with a 3.9% gain.

The standout shift is in options positioning. The put/call ratio reached 4.51 on October 26, a 52-week high and more than three standard deviations above its 20-day average of 1.18. That is an extraordinary level of put buying relative to calls, and it has arrived during a period when the stock is actually rising: shares closed at $13.75, up 4% on Monday and 12% over the past month. Heavy demand for downside protection during a rally typically reflects investors locking in gains or hedging an uncertain catalyst rather than outright bearish conviction.

Short selling and borrow conditions tell a different story. Estimated short shares have risen roughly 15% over the past month to around 27.9 million, and FINRA's fortnightly data puts days to cover at 8.45, suggesting it would take bears over a week of typical volume to exit. Yet the lending market itself remains relaxed: borrow availability stands at 132%, meaning there is roughly 1.3 shares available to lend for every share already borrowed, and the cost to borrow has fallen a third over the past month to just 0.55%. Short interest at these levels is elevated relative to recent history, but the comfortable availability means there is no mechanical squeeze pressure heading into the print.

The analyst picture is complicated by data inconsistency. The most recent action of note was Citigroup's upgrade to Buy in late September, with a target of 1,450 rupees on the Indian-listed shares, a signal of renewed conviction from a major firm. Other analyst data in the record spans multiple years and currencies, making a clean consensus picture difficult to construct, and should be treated with caution. What is clearer is that the company trades at a forward PE of around 22 and an EV/EBITDA of roughly 14, multiples that have expanded meaningfully over the past month alongside the share price recovery.

Chairman K. Satish Reddy holds a 13D filing disclosing a 13.58% stake, which is notable: a Schedule 13D indicates active rather than passive intent. BlackRock holds around 4% on a passive 13G basis. The founder concentration means the float available to trade is materially smaller than the total share count, which amplifies the significance of any shift in institutional positioning around results. Thursday's print will test whether the recent price recovery and the record put/call ratio reflect a market genuinely braced for a downside surprise, or simply caution around a quarter that has already partly played out.